BFC Planning’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$32.9K Buy
87
+52
+149% +$18.2K ﹤0.01% 1769
2026
Q2
$10.3K Sell
35
-9
-20% -$2.55K ﹤0.01% 2360
2026
Q1
$12.3K Hold
44
– – ﹤0.01% 1943
2025
Q4
$13.3K Hold
44
– – ﹤0.01% 1940
2025
Q3
$12.3K Hold
44
– – ﹤0.01% 1809
2025
Q2
$10.6K Buy
44
+5
+13% +$1.18K ﹤0.01% 1770
2025
Q1
$9.5K Buy
39
+9
+30% +$2.71K ﹤0.01% 1787
2024
Q4
$9.9K Sell
30
-5
-14% -$1.7K ﹤0.01% 1771
2024
Q3
$11.7K Buy
+35
New +$11.1K ﹤0.01% 1679

Other funds holding BIO

BFC Planning's BIO Position: Q3 2026 in Review

BFC Planning increased its Bio-Rad Laboratories Class A (BIO) stake by 149% in Q3 2026, buying an estimated $18.2K and bringing the position to 87 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1769.

BFC Planning first reported a position in BIO in Q3 2024 and has held it in 9 quarters since. 339 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • BFC Planning held 87 shares of Bio-Rad Laboratories Class A worth $32.9K as of Q3 2026.
  • BFC Planning bought 52 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $18.2K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1769 holding.
  • BFC Planning first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 9 quarters since.
  • 339 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.